Spera AM, Pagliano P, Conti V. Hepatitis C virus eradication in people living with human immunodeficiency virus: Where are we now? World J Hepatol 2024; 16(5): 661-666 [PMID: 38818300 DOI: 10.4254/wjh.v16.i5.661]
Corresponding Author of This Article
Anna Maria Spera, MD, PhD, Doctor, Postdoctoral Fellow, Infectious Disease Unit, Universitary Hospital OORR San Giovanni di Dio e Ruggi d'Aragona, Largo Ippocrate, Salerno 84131, Italy. annamariaspera@hotmail.it
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. May 27, 2024; 16(5): 661-666 Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.661
Hepatitis C virus eradication in people living with human immunodeficiency virus: Where are we now?
Anna Maria Spera, Pasquale Pagliano, Valeria Conti
Anna Maria Spera, Infectious Disease Unit, Universitary Hospital OORR San Giovanni di Dio e Ruggi d'Aragona, Salerno 84131, Italy
Pasquale Pagliano, Department of Infectious Diseases, University of Salerno, Salerno 84131, Italy
Valeria Conti, Clinical Pharmacology and Pharmacogenetics Unit, University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, Salerno 84131, Italy
Author contributions: All authors contributed equally to the work.
Conflict-of-interest statement: All authors declare no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Anna Maria Spera, MD, PhD, Doctor, Postdoctoral Fellow, Infectious Disease Unit, Universitary Hospital OORR San Giovanni di Dio e Ruggi d'Aragona, Largo Ippocrate, Salerno 84131, Italy. annamariaspera@hotmail.it
Received: December 26, 2023 Revised: March 6, 2024 Accepted: April 15, 2024 Published online: May 27, 2024 Processing time: 147 Days and 12.4 Hours
Core Tip
Core Tip: Considering the quite high prevalence of hepatitis C virus (HCV) co-infection in people living with human immunodeficiency virus (PLWH), along with the interplay of HCV and human immunodeficiency virus infections, the usefulness of direct acting antivirals (DAAs) therapy regimen for the cure of HCV in this context appears crucial. However, apart from several known drug-drug interactions between highly active antiretroviral therapy (HAART) and DAAs, the metabolic impact of HCV eradication in terms of worsening of lipid profile as well as the improvement of glucose metabolism must be taken into account. The treatment of HCV infection in PLWH under HAART represents a challenge as well as a great opportunity for clinicians and deserves attention.
